期刊文献+

炎症相关性指标在评价强直性脊柱炎活动性中的价值 被引量:6

Significance of inflammation indexes in disease activity assessment of ankylosing spondylitis
下载PDF
导出
摘要 目的探讨强直性脊柱炎(ankylosing spondylitis,AS)患者各炎症相关性指标与疾病活动性的相关性。方法依据Bath强直性脊柱炎活动性指标(BASDAI)将60例AS患者分为36例活动组和24例静止组,比较2组AS患者的各项实验室指标,并与30例健康对照者做对比。结果活动组AS患者ESR、CRP、IgA、IgG明显高于与静止组和正常对照组(P<0.01),而WBC、PLT、IgM、C3、C4无统计学差异(P>0.05);ESR、CRP、IgA与BASDAI存在正相关(P<0.01);IgA与ESR、CRP存在正相关(P<0.01)。结论除了ESR和CRP外,IgA也可作为反映AS疾病活动性的一项实验室指标。 We aim to explore the correlation between inflammation indexes with disease activity in ankylosing spondylitis (AS) patients. According to the BASDAI index, 60 AS patients were divided into activity group and static group, then we compared the laboratory parameters among active group, static group, and normal group. The results showed that the ESR, CRP, IgA and IgG levels in activity group were significantly higher than that in static group or normal group (P 〈 0.01), but the WBC, PLT, IgM, C3, C4 level showed no significant difference in the 3 groups (P 〉 0.05). Furthermore, The ESR, CRP, IgA levels were positively correlation with the BASDAI index (P 〈 0.01), and the IgA was positively correlated with ESR and CRP (P 〈 0.01). The data imply that besides the ESR and CRP, The IgA can also be a laboratory parameter to assess AS disease activity.
出处 《免疫学杂志》 CAS CSCD 北大核心 2011年第11期1011-1012,共2页 Immunological Journal
关键词 强直性脊柱炎 疾病活动性 免疫球蛋白A Ankylosing spondylitis Disease activity Immuneglobulin A
  • 相关文献

参考文献3

二级参考文献49

  • 1陈蕊雯,王勇,孙树汉,段世伟.强直性脊柱炎易感基因的研究进展[J].Acta Genetica Sinica,2005,32(10):1108-1114. 被引量:22
  • 2[1]Beutler BA.The role of tumor necrosis factor in health anddisease.J Rheumatol,1999,57(1):16-21.
  • 3[2]Braun J,Bollow M,Neure L,et al.Use of immunohistologic and insitu hybridization techniques in the examination of sacroiliac jointbiopsy specimens from patients with ankylosing spondylitis.Arthritis Rheum,1995,38(4): 499-505.
  • 4[3]Brandt J,Haibel H,Sieper J,et al.Infliximab treatment of severeankylosing spondylitis:one-year follow-up.Arthritis Rheum,2002,44(12):2936-2945.
  • 5[4]Brandt J,Haibel H,Cornely D,et al.Successful treatment of activeankylosing spondylitis with the anti-tumor necrosis factor-αmonoclonal antibody infliximab.Arthritis Rheu,2000,43(6):1346-1352.
  • 6[5]Braun J,Brandt J,Listin J,et al.Treatment of active ankylosingspondylitis with infliximab: a randomized controlled multicentertrial.Lancet,2002,359(9313): 1187-1193.
  • 7[8]Gu J,Rihl M,Marker-Hermann E,et al.Clues to pathogenesis ofSpondyloarthropathy derived from synovial-fluid-mononuclearcell gene expression profiles.J Rheumatol,2002,29(10):2159-64.
  • 8[9]Seta N,Granfors K,Sahly H,et al.Expression of host defensescavenger receptors in spondyloarthropathy.Arthritis Rheum,2001,44(4): 931-939
  • 9[10]Elsen M,Spellman P,Brown P,et al.Cluster analysis and display ofgenome-wide expression patterns.Proc Natl Acad Sci USA,1998,95:14863-14868.
  • 10[11]Cunnane G,Fitzgerald O,Beeton C,et al.Early joint erosions andserum levels of matrix metalloproteinase 1,matrix metalloproteinase3,and tissue inhibitor of metalloproteinases 1 in rheumatoidarthritis.Arthritis Rheum,2002,44(10):2263-2274.

共引文献32

同被引文献38

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部